Dysmenorrhea – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：54頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Dysmenorrhea – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Dysmenorrhea - Pipeline Review, H2 2012', provides an overview of the Dysmenorrhea therapeutic pipeline. This report provides information on the therapeutic development for Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dysmenorrhea. 'Dysmenorrhea - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Dysmenorrhea.
- A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dysmenorrhea pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dysmenorrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dysmenorrhea pipeline depth and focus of Dysmenorrhea therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Dysmenorrhea - Pipeline Review, H2 2012', provides an overview of the Dysmenorrhea therapeutic pipeline. This report provides information on the therapeutic development for Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dysmenorrhea. 'Dysmenorrhea - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Dysmenorrhea.
- A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dysmenorrhea pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dysmenorrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dysmenorrhea pipeline depth and focus of Dysmenorrhea therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Dysmenorrhea Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Dysmenorrhea 8
Dysmenorrhea Therapeutics under Development by Companies 10
Dysmenorrhea Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Dysmenorrhea Therapeutics – Products under Development by Companies 16
Dysmenorrhea Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Dysmenorrhea Therapeutics Development 18
Columbia Laboratories Inc. 18
China Aoxing Pharmaceutical Co., Inc 19
PDC Biotech GmbH 20
Nobelpharma Co., Ltd. 21
Vantia Therapeutics 22
Dysmenorrhea – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Peptidometics - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PDC41 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PDC31 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Lidocaine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VA111913 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Viagra - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gestodene + Ethinyl Estradiol - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Fenellin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tongjingshule - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NPC-01 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Mefenamic Acid - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Colpermin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Zinc - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Omega-3 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
T109 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Dysmenorrhea Therapeutics – Discontinued Products 45
Dysmenorrhea Therapeutics - Dormant Products 46
Dysmenorrhea – Product Development Milestones 47
Featured News & Press Releases 47
Jul 19, 2010: Aoxing Pharma Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 47
Jul 19, 2010: Aoxing Pharmaceutical Company Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 47
Mar 26, 2010: Vantia Therapeutics Reveals Structure Of Its Novel Small Molecule Treatment For Dysmenorrhoea, VA111913 48
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea 48
Jan 05, 2010: China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug 49
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 50
Nov 09, 2007: Merck Agreement to Resolve U.S. VIOXX Product Liability Lawsuits 50
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 50
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 51
Apr 30, 2007: Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Number of Products Under Development for Dysmenorrhea, H2 2012 8
Products under Development for Dysmenorrhea – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Columbia Laboratories Inc., H2 2012 18
China Aoxing Pharmaceutical Co., Inc, H2 2012 19
PDC Biotech GmbH, H2 2012 20
Nobelpharma Co., Ltd., H2 2012 21
Vantia Therapeutics, H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Dysmenorrhea Therapeutics – Discontinued Products 45
Dysmenorrhea Therapeutics – Dormant Products 46
List of Figures
Number of Products under Development for Dysmenorrhea, H2 2012 8
Products under Development for Dysmenorrhea – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Dysmenorrhea Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Dysmenorrhea 8
Dysmenorrhea Therapeutics under Development by Companies 10
Dysmenorrhea Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Dysmenorrhea Therapeutics – Products under Development by Companies 16
Dysmenorrhea Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Dysmenorrhea Therapeutics Development 18
Columbia Laboratories Inc. 18
China Aoxing Pharmaceutical Co., Inc 19
PDC Biotech GmbH 20
Nobelpharma Co., Ltd. 21
Vantia Therapeutics 22
Dysmenorrhea – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Peptidometics - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PDC41 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PDC31 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Lidocaine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VA111913 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Viagra - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gestodene + Ethinyl Estradiol - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Fenellin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Tongjingshule - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NPC-01 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Mefenamic Acid - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Colpermin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Zinc - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Omega-3 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
T109 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Dysmenorrhea Therapeutics – Discontinued Products 45
Dysmenorrhea Therapeutics - Dormant Products 46
Dysmenorrhea – Product Development Milestones 47
Featured News & Press Releases 47
Jul 19, 2010: Aoxing Pharma Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 47
Jul 19, 2010: Aoxing Pharmaceutical Company Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 47
Mar 26, 2010: Vantia Therapeutics Reveals Structure Of Its Novel Small Molecule Treatment For Dysmenorrhoea, VA111913 48
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea 48
Jan 05, 2010: China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug 49
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 50
Nov 09, 2007: Merck Agreement to Resolve U.S. VIOXX Product Liability Lawsuits 50
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 50
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 51
Apr 30, 2007: Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Number of Products Under Development for Dysmenorrhea, H2 2012 8
Products under Development for Dysmenorrhea – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Columbia Laboratories Inc., H2 2012 18
China Aoxing Pharmaceutical Co., Inc, H2 2012 19
PDC Biotech GmbH, H2 2012 20
Nobelpharma Co., Ltd., H2 2012 21
Vantia Therapeutics, H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Dysmenorrhea Therapeutics – Discontinued Products 45
Dysmenorrhea Therapeutics – Dormant Products 46
List of Figures
Number of Products under Development for Dysmenorrhea, H2 2012 8
Products under Development for Dysmenorrhea – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28
